Brivaracetam for the treatment of epilepsy in adults

References

• De Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 2008;12(4):540-6
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48(12):2224-33
   PubMed Web of Science ®Google Scholar
• Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy in the United States. Epilepsia 2009;50(10):2186-91
   PubMed Web of Science ®Google Scholar
• Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42(6):796-803
   PubMed Web of Science ®Google Scholar
• Berg AT, Shinnar S, Levy SR, et al. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 2000;41(10):1269-75
   PubMed Web of Science ®Google Scholar
• Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 2011;664(1-3):36-44
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154(8):1662-71
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008;54(4):715-20
   PubMed Web of Science ®Google Scholar
• Zona C, Pieri M, Carunchio I, et al. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res 2010;88(1):46-54
   PubMed Web of Science ®Google Scholar
• Margineanu DG, Klitgaard H. Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. Seizure 2009;18(6):453-6
   PubMedGoogle Scholar
• Mula M. Investigating psychotropic properties of antiepileptic drugs. Expert Rev Neurother 2013;13(6):639-46
   PubMed Web of Science ®Google Scholar
• Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav 2013;26(3):440-9
   PubMed Web of Science ®Google Scholar
• Helmstaedter C, Mihov Y, Toliat MR, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia 2013;54(1):36-44
   PubMedGoogle Scholar
• Von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics 2007;4(1):84-7
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2007;63(6):680-8
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008;66(1):71-5
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013;103(1):2-30
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92(2-3):89-124
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol 2012;52(12):1927-33
   PubMed Web of Science ®Google Scholar
• Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 2013;53(6):633-41
   PubMed Web of Science ®Google Scholar
• Stockis A, Rolan P. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol 2013;53(12):1313-21
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A, Von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75(6):519-25
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013;54(1):89-97
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55(1):47-5
   PubMed Web of Science ®Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55(1):57-66
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55(1):38-46
   PubMed Web of Science ®Google Scholar
• Rosillon D, Astruc B, Hulhoven R, et al. Effect of brivaracetam on cardiac repolarisation – a thorough QT study. Curr Med Res Opin 2008;24(8):2327-37
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69(10):1027-34
   PubMed Web of Science ®Google Scholar
• Perucca E. What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? Epileptic Disord 2012;14(2):124-31
   PubMedGoogle Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069-77
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010;51(1):7-26
   PubMed Web of Science ®Google Scholar
• Gao L, Xia L, Zhao FL, Li SC. Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res 2013;103(1):31-44
   PubMed Web of Science ®Google Scholar
• Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007;30(7):555-67
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009;11(1):1-9
   PubMed Web of Science ®Google Scholar
• Meador KJ, Gevins A, Leese PT, et al. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia 2011;52(2):264-72
   PubMed Web of Science ®Google Scholar